Chemical Structure (Pregabalin 01)
Pregabalin Capsule
Product Images NDC 69367-331
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 69367-331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pregabalin 02)
This is a table that shows the percent improvement in pain from baseline for different doses of Pregabalin and a Placebo. The "Percent of Patients Improved" is 100%.*
Figure 2 (Pregabalin 03)
This appears to be a graph or chart showing the percentage of patients who experienced improvement while taking Pregabalin 100mg three times a day compared to a placebo. It also includes a scale measuring the percentage improvement in pain from the baseline.*
Figure 3 (Pregabalin 04)
This is a table displaying different doses of Pregabalin administered two times a day and a placebo. The table shows the percent of patients improved at different levels of pain improvement (represented in numbers along the bottom of the table). There is no additional information available.*
Figure 4 (Pregabalin 05)
This is a chart presenting the results of a study evaluating the effects of pregabalin on pain management. The chart shows the percentage of patients who reported improvement in their pain levels compared to their baseline levels after receiving different dosages of pregabalin or placebo. The dosages reported are 100 mg and 200 mg of pregabalin taken three times a day and a placebo. There is not enough context to determine the type of pain or illness that was studied.*
Figure 5 (Pregabalin 06)
This is a graph showing the percentage of patients who have improved pain after taking Pregabalin at doses of 50mg three times a day and 100mg three times a day, compared to a placebo. The x-axis shows the percent improvement in pain from baseline, while the y-axis shows the number of patients. The graph indicates that 100% of patients experienced improvement with Pregabalin at a dose of 100mg three times a day, while only some patients experienced improvement with Pregabalin at a dose of 50mg three times a day and placebo.*
Figure 6 (Pregabalin 07)
This is a table presenting different studies (E1 and E3), treatments (Placebo, 50mg/day, 150mg/day, 300mg/day, 600mg/day), and the number of subjects participating in the studies (N). There are also some numerical values and symbols that seem to be placeholders, such as 519, 319, & and @. No further information or context is available.*
Figure 7 (Pregabalin 08)
Figure 9 (Pregabalin 09)
This is a graph showing the percent of patients who improved in pain from the baseline after taking different daily doses of pregabalin, including a placebo. The text also shows that the highest improvement was achieved with a daily dose of 600mg.*
Figure 10 (Pregabalin 10)
Figure 11 (Pregabalin 11)
This is a data table showing the percentage of subjects that improved from baseline to week 12 on pregabalin and placebo. The first row indicates that 100% of the subjects improved, while the subsequent row shows numerical values for improving percentage corresponding to specified time intervals. However, further context regarding the study or subject matter is not available.*
Figure 12 (Pregabalin 12)
The text is describing a chart or graph showing the percentage of subjects who saw improvement from baseline to week 16 in a clinical trial. The chart includes different numbers representing the percentage of improvement for each data point. The data includes a comparison between a treatment group (Progateiin) and a placebo group. The percentage of improvement for Progateiin is shown to be 100%.*
Principal Display Panel (25 mg Capsule Bottle Label)
This is a medication description for Pregabalin capsules containing 25 g of the drug. The dosage and usage details are not available, as they are mentioned in the accompanying prescribing guide. The capsules should be dispensed in child-resistant containers. The manufacturer is ScleGen Pharmaceuticals Inc. and the medication is manufactured for Westminster Pharmaceuticals LLC. The NDC code for the medication is 69367-324-09 and the package contains 90 capsules.*
Principal Display Panel (50 mg Capsule Bottle Label)
This text describes a medication called Pregabalin available in capsules form. The packaging contains 90 capsules with each capsule containing 50mg of the medication. The recommended dosage and usage instructions are not mentioned in the text and are supposed to be provided in an accompanying prescription information. The medication should be stored within a temperature range between 9°F to 86°F and dispensed in child-resistant containers. The manufacturer is mentioned as Ren. 05721 Sciefen Pharmaceuticals, located in Hauppauge, NY 11788, and the medication is manufactured for Westminster Pharmaceuticals, LLC based in Nashville, TH 37217. The text also displays the NDC number and the manufacturing date code (L1017). It is advised to provide the patient with an accompanying medication guide.*
Principal Display Panel (75 mg Capsule Bottle Label)
This is a medication information for Pregabalin capsules containing 75 mg of the drug. The dosage and usage details are not provided and one needs to refer to the accompanying prescribing information for the same. The medication should be stored at a temperature between 15°C to 30°C (50 to 86°F) and dispensed in child-resistant containers. The manufacturer and distributer information is provided along with the National Drug Code (NDC) number. A medication guide should be provided to each patient receiving the medication.*
Principal Display Panel (100 mg Capsule Bottle Label)
This is a medication called Pregabalin, which comes in capsule form with 100mg strength, and should be stored within a temperature range of 15°C to 30°C. The recommended dosage and usage instruction can be found in the accompanying prescription label. The medication should be dispensed in a tight, child-resistant container, and the patient should also receive a medication guide. The manufacturer of this medication is Westminster Pharmaceuticals LLC, located in Nashville, Tennessee. The identified National Drug Code is 69367-327-09.*
Principal Display Panel (150 mg Capsule Bottle Label)
Each capsule contains 160 mg Pregabalin. It is a medication prescribed for controlling seizures, nerve pain, and anxiety disorders. Dispense in a tight, child-resistant container at a controlled room temperature. The package contains 90 capsules and comes with a medication guide to be given to each patient. Manufactured by Westminster Pharmaceuticals LLC, it is available at pharmacies with an NDC code 69367-328-09.*
Principal Display Panel (200 mg Capsule Bottle Label)
This is a medication label of capsules containing 200 g of Regabain. It provides information on dosage, storage, and dispensing of the capsules. The capsules should be kept in a tightly sealed, child-resistant container between 15-30 degrees Celsius. It also lists the NDC number and manufacturing information for ScleGen Pharmaceuticals. Additionally, it mentions that a medication guide should be given to each patient and that the capsules are manufactured for Westminster Pharmaceuticals.*
Principal Display Panel (225 mg Capsule Bottle Label)
This is a medication called Pregabalin available in the form of capsules containing 225g each. Dosage and usage information is not available in this text, and it is advised to refer to the prescribing information. The medication should be stored at a controlled room temperature between 25°C to 30°C in tight and child-resistant containers. The manufacturer is Ren 05721 Sciefen Pharmaceuticals, located in Hauppauge, NY 11788, and the medication is distributed by Westminster Pharmaceuticals, LLC, located in Nashvile, TH 37217. The National Drug Code (NDC) for the medication is 69367-330-09, and it comes with a medical guide per patient.*
Principal Display Panel (300 mg Capsule Bottle Label)
Each capsule contains 300 mg of pregabalin. This medicine is dispensed in tight child-resistant USP capsules and should be stored at a controlled room temperature between 15°C to 30°C (59 to 86°F). Dosage and use information can be found in the accompanying prescribing information and medication guide provided to each patient. The medicine is manufactured by Westminster Pharmaceuticals LLC and comes in a package of 90 capsules with an NDC number of 69367-331-09.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
